{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:48:41Z","timestamp":1790624921064,"version":"4.1.0"},"reference-count":133,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Physiol."],"DOI":"10.3389\/fphys.2020.00435","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T13:54:58Z","timestamp":1589982898000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":169,"title":["Recent Advances in the Treatment of Sickle Cell Disease"],"prefix":"10.3389","volume":"11","author":[{"given":"Gabriel","family":"Salinas Cisneros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swee L.","family":"Thein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1182\/blood.V90.5.2041","article-title":"RheothRx (poloxamer 188) injection for the acute painful episode of sickle cell disease: a pilot study.","volume":"90","author":"Adams-Graves","year":"1997","journal-title":"Blood"},{"key":"B2","doi-asserted-by":"publisher","first-page":"811","DOI":"10.3324\/haematol.2013.099747","article-title":"Hematopoietic stem cell transplantation in thalassemia major and sickle cell disease: indications and management recommendations from an international expert panel.","volume":"99","author":"Angelucci","year":"2014","journal-title":"Haematologica"},{"key":"B3","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1056\/NEJMoa1611770","article-title":"Crizanlizumab for the prevention of pain crises in sickle cell disease.","volume":"376","author":"Ataga","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3991","DOI":"10.1182\/blood-2007-08-110098","article-title":"Efficacy and safety of the Gardos channel blocker, senicapoc (ICA-17043), in patients with sickle cell anemia.","volume":"111","author":"Ataga","year":"2008","journal-title":"Blood"},{"key":"B5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1517\/13543780802708011","article-title":"Senicapoc (ICA-17043): a potential therapy for the prevention and treatment of hemolysis-associated complications in sickle cell anemia.","volume":"18","author":"Ataga","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1182\/blood-2014-01-543652","article-title":"Acid sphingomyelinase is activated in sickle cell erythrocytes and contributes to inflammatory microparticle generation in SCD.","volume":"124","author":"Awojoodu","year":"2014","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1126\/science.1242088","article-title":"An erythroid enhancer of BCL11A subject to genetic variation determines fetal hemoglobin level.","volume":"342","author":"Bauer","year":"2013","journal-title":"Science"},{"key":"B8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3324\/haematol.2018.213207","article-title":"Long-term event-free survival, chimerism and fertility outcomes in 234 patients with sickle-cell anemia younger than 30 years after myeloablative conditioning and matched-sibling transplantation in France.","volume":"105","author":"Bernaudin","year":"2020","journal-title":"Haematologica"},{"key":"B9","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3324\/haematol.11515","article-title":"Influence of sickle cell disease and treatment with hydroxyurea on sperm parameters and fertility of human males.","volume":"93","author":"Berthaut","year":"2008","journal-title":"Haematologica"},{"key":"B10","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/1060028016681129","article-title":"Outcomes of rivaroxaban use in patients with sickle cell disease.","volume":"51","author":"Bhat","year":"2017","journal-title":"Ann. Pharmacother."},{"key":"B11","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1016\/S2352-3026(19)30031-6","volume":"6","author":"Bolanos-Meade","year":"2019","journal-title":"Lancet Haematol."},{"key":"B12","doi-asserted-by":"publisher","first-page":"4285","DOI":"10.1182\/blood-2012-07-438408","article-title":"HLA-haploidentical bone marrow transplantation with post-transplant cyclophosphamide expands the donor pool for patients with sickle cell disease.","volume":"120","author":"Bolanos-Meade","year":"2012","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","first-page":"770","DOI":"10.3324\/haematol.2017.187047","article-title":"Safety and efficacy of plerixafor dose escalation for the mobilization of CD34(+) hematopoietic progenitor cells in patients with sickle cell disease: interim results.","volume":"103","author":"Boulad","year":"2018","journal-title":"Haematologica"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1182\/blood-2016-01-691089","article-title":"Forced chromatin looping raises fetal hemoglobin in adult sickle cells to higher levels than pharmacologic inducers.","volume":"128","author":"Breda","year":"2016","journal-title":"Blood"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3868","DOI":"10.1172\/JCI87885","article-title":"Lineage-specific BCL11A knockdown circumvents toxicities and reverses sickle phenotype.","volume":"126","author":"Brendel","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B16","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood.V65.1.183.183","article-title":"Hemoglobin S polymerization: primary determinant of the hemolytic and clinical severity of the sickling syndromes.","volume":"65","author":"Brittenham","year":"1985","journal-title":"Blood"},{"key":"B17","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1111\/bjh.14655","article-title":"Increased incidence of VTE in sickle cell disease patients: risk factors, recurrence and impact on mortality.","volume":"178","author":"Brunson","year":"2017","journal-title":"Br. J. Haematol."},{"key":"B18","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1056\/NEJM199709113371107","article-title":"Pathogenesis and treatment of sickle cell disease.","volume":"337","author":"Bunn","year":"1997","journal-title":"N. Engl. J. Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1016\/j.ymthe.2017.03.024","article-title":"Gene therapy for beta-hemoglobinopathies.","volume":"25","author":"Cavazzana","year":"2017","journal-title":"Mol. Ther."},{"key":"B20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1038\/nature09328","article-title":"Transfusion independence and HMGA2 activation after gene therapy of human beta-thalassaemia.","volume":"467","author":"Cavazzana-Calvo","year":"2010","journal-title":"Nature"},{"key":"B21","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1182\/bloodadvances.2019001143","article-title":"American society of hematology 2020 guidelines for sickle cell disease: transfusion support.","volume":"4","author":"Chou","year":"2020","journal-title":"Blood Adv."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1182\/blood-2018-05-851360","article-title":"RH genotype matching for transfusion support in sickle cell disease.","volume":"132","author":"Chou","year":"2018","journal-title":"Blood"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1062","DOI":"10.1182\/blood-2013-03-490623","article-title":"High prevalence of red blood cell alloimmunization in sickle cell disease despite transfusion from RH-matched minority donors.","volume":"122","author":"Chou","year":"2013","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1172\/JCI16672","article-title":"Hydroxyurea induces fetal hemoglobin by the nitric oxide-dependent activation of soluble guanylyl cyclase.","volume":"111","author":"Cokic","year":"2003","journal-title":"J. Clin. Invest."},{"key":"B25","doi-asserted-by":"publisher","first-page":"263","DOI":"10.3233\/CH-189012","article-title":"Inflammation in sickle cell disease.","volume":"68","author":"Conran","year":"2018","journal-title":"Clin. Hemorheol. Microcirc."},{"key":"B26","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1080\/13543784.2017.1335710","article-title":"Prasugrel hydrochloride for the treatment of sickle cell disease.","volume":"26","author":"Conran","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"B27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1111\/cts.12005","article-title":"Effect of propranolol as antiadhesive therapy in sickle cell disease.","volume":"5","author":"De Castro","year":"2012","journal-title":"Clin. Transl. Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1586\/17474086.2014.959922","article-title":"Hydroxyurea therapy contributes to infertility in adult men with sickle cell disease: a review.","volume":"7","author":"DeBaun","year":"2014","journal-title":"Expert Rev. Hematol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature20134","article-title":"CRISPR\/Cas9 beta-globin gene targeting in human haematopoietic stem cells.","volume":"539","author":"Dever","year":"2016","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1182\/blood-2017-02-765891","article-title":"Treating sickle cell disease by targeting HbS polymerization.","volume":"129","author":"Eaton","year":"2017","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1002\/ajh.23683","article-title":"Factors associated with survival in a contemporary adult sickle cell disease cohort.","volume":"89","author":"Elmariah","year":"2014","journal-title":"Am. J. Hematol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1053\/j.seminhematol.2018.04.014","article-title":"Genetic therapies for sickle cell disease.","volume":"55","author":"Esrick","year":"2018","journal-title":"Semin. Hematol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1182\/bloodadvances.2018016725","article-title":"Successful hematopoietic stem cell mobilization and apheresis collection using plerixafor alone in sickle cell patients.","volume":"2","author":"Esrick","year":"2018","journal-title":"Blood Adv."},{"key":"B34","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1002\/ajh.24019","article-title":"Inactivation of HDAC1 or HDAC2 induces gamma globin expression without altering cell cycle or proliferation.","volume":"90","author":"Esrick","year":"2015","journal-title":"Am. J. Hematol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.hoc.2014.08.014","article-title":"Hematopoietic stem cell transplantation for patients with sickle cell disease: progress and future directions.","volume":"28","author":"Fitzhugh","year":"2014","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1182\/blood-2017-03-772392","article-title":"At least 20% donor myeloid chimerism is necessary to reverse the sickle phenotype after allogeneic HSCT.","volume":"130","author":"Fitzhugh","year":"2017","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1182\/blood-2016-05-716910","article-title":"Survival in adults with sickle cell disease in a high-income setting.","volume":"128","author":"Gardner","year":"2016","journal-title":"Blood"},{"key":"B38","first-page":"371","article-title":"Genetic factors modifying sickle cell disease severity","author":"Gardner","year":"2016","journal-title":"Sickle Cell Anemia - From Basic Science to Clinical Practice"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1182\/blood-2016-10-745711","article-title":"Sickle cell disease: an international survey of results of HLA-identical sibling hematopoietic stem cell transplantation.","volume":"129","author":"Gluckman","year":"2017","journal-title":"Blood"},{"key":"B40","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1016\/S0021-9258(18)67935-9","article-title":"The structure of human hemoglobin: VI. The sequence of amino acids in the tryptic peptides of the \u03b2 chain.","volume":"238","author":"Goldstein","year":"1963","journal-title":"J. Biol. Chem."},{"key":"B41","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1053\/j.seminhematol.2018.04.011","article-title":"Curative therapies: allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.","volume":"55","author":"Guilcher","year":"2018","journal-title":"Semin. Hematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1111\/bjh.13028","article-title":"Red blood cells of sickle cell disease patients exhibit abnormally high abundance of N-methyl D-aspartate receptors mediating excessive calcium uptake.","volume":"167","author":"Hanggi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"S512","DOI":"10.1016\/j.amepre.2009.12.022","article-title":"Population estimates of sickle cell disease in the U.S.","volume":"38","author":"Hassell","year":"2010","journal-title":"Am. J. Prev. Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.amepre.2015.11.002","article-title":"Sickle cell disease: a continued call to action.","volume":"51","author":"Hassell","year":"2016","journal-title":"Am. J. Prev. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/ajh.21952","article-title":"Reconstructing sickle cell disease: a data-based analysis of the \u201chyperhemolysis paradigm\u201d for pulmonary hypertension from the perspective of evidence-based medicine.","volume":"86","author":"Hebbel","year":"2011","journal-title":"Am. J. Hematol."},{"key":"B46","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/ajh.24975","article-title":"Sickle hemoglobin oxygen affinity-shifting strategies have unequal cerebrovascular risks.","volume":"93","author":"Hebbel","year":"2018","journal-title":"Am. J. Hematol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1056\/NEJMoa1512021","article-title":"A multinational trial of prasugrel for sickle cell vaso-occlusive events.","volume":"374","author":"Heeney","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1182\/blood-2018-07-865634","article-title":"Rhesus pieces: genotype matching of RBCs.","volume":"132","author":"Hendrickson","year":"2018","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1001\/jama.2014.11011","article-title":"Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia.","volume":"6","author":"Herrick","year":"1910","journal-title":"Arch. Intern. Med."},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2014.11011","article-title":"Peculiar elongated and sickle-shaped red blood corpuscles in a case of severe anemia.","volume":"312","author":"Herrick","year":"2014","journal-title":"JAMA"},{"key":"B51","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1111\/bjh.14580","article-title":"Simvastatin reduces vaso-occlusive pain in sickle cell anaemia: a pilot efficacy trial.","volume":"177","author":"Hoppe","year":"2017","journal-title":"Br. J. Haematol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1182\/asheducation-2016.1.625","article-title":"Sickle cell disease: when and how to transfuse.","volume":"2016","author":"Howard","year":"2016","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B53","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/S0140-6736(12)61726-7","article-title":"The transfusion alternatives preoperatively in sickle cell disease (TAPS) study: a randomised, controlled, multicentre clinical trial.","volume":"381","author":"Howard","year":"2013","journal-title":"Lancet"},{"key":"B54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1001\/jama.2014.7192","article-title":"Nonmyeloablative HLA-matched sibling allogeneic hematopoietic stem cell transplantation for severe sickle cell phenotype.","volume":"312","author":"Hsieh","year":"2014","journal-title":"JAMA"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1056\/NEJMoa0904971","article-title":"Allogeneic hematopoietic stem-cell transplantation for sickle cell disease.","volume":"361","author":"Hsieh","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B56","doi-asserted-by":"publisher","first-page":"749","DOI":"10.3324\/haematol.2018.190876","article-title":"Hematopoietic stem cell mobilization with plerixafor in sickle cell disease.","volume":"103","author":"Hsieh","year":"2018","journal-title":"Haematologica"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.3324\/haematol.2016.149427","article-title":"Comparison of graft-versus-host disease-free, relapse-free survival according to a variety of graft sources: antithymocyte globulin and single cord blood provide favorable outcomes in some subgroups.","volume":"101","author":"Inamoto","year":"2016","journal-title":"Haematologica"},{"key":"B58","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1097\/00043426-198507030-00008","article-title":"Bone marrow transplantation in the treatment of sickle cell anemia.","volume":"7","author":"Johnson","year":"1985","journal-title":"Am. J. Pediatr. Hematol. Oncol."},{"key":"B59","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1056\/NEJM198409203111207","article-title":"Bone-marrow transplantation in a patient with sickle-cell anemia.","volume":"311","author":"Johnson","year":"1984","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.3390\/ijerph6031124","article-title":"Adverse effects of a clinically relevant dose of hydroxyurea used for the treatment of sickle cell disease on male fertility endpoints.","volume":"6","author":"Jones","year":"2009","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"B61","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1053\/j.seminhematol.2018.04.013","article-title":"When there is no match, the game is not over: alternative donor options for hematopoietic stem cell transplantation in sickle cell disease.","volume":"55","author":"Joseph","year":"2018","journal-title":"Semin. Hematol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.1016\/j.bbmt.2012.01.019","article-title":"Unrelated donor cord blood transplantation for children with severe sickle cell disease: results of one cohort from the phase II study from the blood and marrow transplant clinical trials network (BMT CTN).","volume":"18","author":"Kamani","year":"2012","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B63","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1111\/bjh.15646","article-title":"Ticagrelor does not impact patient-reported pain in young adults with sickle cell disease: a multicentre, randomised phase IIB study.","volume":"184","author":"Kanter","year":"2019","journal-title":"Br. J. Haematol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/ajh.25308","article-title":"Effect of crizanlizumab on pain crises in subgroups of patients with sickle cell disease: a SUSTAIN study analysis.","volume":"94","author":"Kutlar","year":"2019","journal-title":"Am. J. Hematol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3324\/haematol.2017.184788","article-title":"Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion.","volume":"103","author":"Lagresle-Peyrou","year":"2018","journal-title":"Haematologica"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16437","article-title":"Curative options for sickle cell disease: haploidentical stem cell transplantation or gene therapy?","author":"Leonard","year":"2020","journal-title":"Br. J. Haematol."},{"key":"B67","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1080\/17474086.2018.1486703","article-title":"Stem cell transplantation in sickle cell disease: therapeutic potential and challenges faced.","volume":"11","author":"Leonard","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"B68","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.cell.2018.03.016","article-title":"Direct promoter repression by BCL11A controls the fetal to adult hemoglobin switch.","volume":"173","author":"Liu","year":"2018","journal-title":"Cell"},{"key":"B69","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1056\/NEJMe1814706","article-title":"Hydroxyurea - an essential medicine for sickle cell disease in Africa.","volume":"380","author":"Luzzatto","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B70","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/s41588-018-0085-0","article-title":"Natural regulatory mutations elevate the fetal globin gene via disruption of BCL11A or ZBTB7A binding.","volume":"50","author":"Martyn","year":"2018","journal-title":"Nat. Genet."},{"key":"B71","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1126\/science.aad3312","article-title":"Transcription factors LRF and BCL11A independently repress expression of fetal hemoglobin.","volume":"351","author":"Masuda","year":"2016","journal-title":"Science"},{"key":"B72","doi-asserted-by":"publisher","first-page":"623","DOI":"10.3324\/haematol.2018.213462","article-title":"A novel, highly potent and selective phosphodiesterase-9 inhibitor for the treatment of sickle cell disease.","volume":"105","author":"McArthur","year":"2019","journal-title":"Haematologica"},{"key":"B73","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jpeds.2014.01.070","article-title":"Sickle cell anemia: an underappreciated and unaddressed contributor to global childhood mortality.","volume":"165","author":"McGann","year":"2014","journal-title":"J. Pediatr."},{"key":"B74","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1056\/NEJM200005253422114","article-title":"Prediction of adverse outcomes in children with sickle cell disease.","volume":"342","author":"Miller","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"B75","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1056\/NEJMe1800976","article-title":"l-glutamine and the dawn of combination therapy for sickle cell disease.","volume":"379","author":"Minniti","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002382","article-title":"Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: a randomized phase 1 study.","volume":"14","author":"Molokie","year":"2017","journal-title":"PLoS Med."},{"key":"B77","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1182\/blood-2007-04-081703","article-title":"Erythrocyte glutamine depletion, altered redox environment, and pulmonary hypertension in sickle cell disease.","volume":"111","author":"Morris","year":"2008","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3170","DOI":"10.1182\/bloodadvances.2019000193","article-title":"Role of the coagulation system in the pathogenesis of sickle cell disease.","volume":"3","author":"Nasimuzzaman","year":"2019","journal-title":"Blood Adv."},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.4103\/2277-9175.98152","article-title":"Viral and nonviral delivery systems for gene delivery.","volume":"1","author":"Nayerossadat","year":"2012","journal-title":"Adv. Biomed. Res."},{"key":"B80","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1089\/hum.2016.007","article-title":"Gene therapy of the beta-hemoglobinopathies by lentiviral transfer of the beta(A(T87Q))-globin gene.","volume":"27","author":"Negre","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002202.pub2","article-title":"Hydroxyurea (hydroxycarbamide) for sickle cell disease.","volume":"4","author":"Nevitt","year":"2017","journal-title":"Cochrane Database. Syst. Rev."},{"key":"B82","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1056\/NEJMoa1715971","article-title":"A phase 3 trial of l-glutamine in sickle cell disease.","volume":"379","author":"Niihara","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B83","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1007\/s00277-011-1404-z","article-title":"N-acetylcysteine reduces oxidative stress in sickle cell patients.","volume":"91","author":"Nur","year":"2012","journal-title":"Ann. Hematol."},{"key":"B84","first-page":"288","article-title":"Cerebrovascular accidents in sickle cell disease: rates and risk factors.","volume":"91","author":"Ohene-Frempong","year":"1998","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1182\/blood-2017-06-788935","article-title":"Novel use of hydroxyurea in an African region with malaria (NOHARM): a trial for children with sickle cell anemia.","volume":"130","author":"Opoka","year":"2017","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1146\/annurev-med-041817-125507","article-title":"Emerging genetic therapy for sickle cell disease.","volume":"70","author":"Orkin","year":"2019","journal-title":"Annu. Rev. Med."},{"key":"B87","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1001\/jama.286.17.2099","article-title":"Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial.","volume":"286","author":"Orringer","year":"2001","journal-title":"JAMA"},{"key":"B88","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1002\/ajh.10321","article-title":"Effects of N-acetylcysteine on dense cell formation in sickle cell disease.","volume":"73","author":"Pace","year":"2003","journal-title":"Am. J. Hematol."},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001484","article-title":"Global burden of sickle cell anaemia in children under five, 2010-2050: modelling based on demographics, excess mortality, and interventions.","volume":"10","author":"Piel","year":"2013","journal-title":"PLoS Med."},{"key":"B90","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1177\/1535370216640385","article-title":"Minireview: clinical severity in sickle cell disease: the challenges of definition and prognostication.","volume":"241","author":"Quinn","year":"2016","journal-title":"Exp. Biol. Med."},{"key":"B91","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1182\/blood-2018-03-834440","article-title":"l-Glutamine for sickle cell anemia: more questions than answers.","volume":"132","author":"Quinn","year":"2018","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease.","volume":"115","author":"Quinn","year":"2010","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1182\/blood-2019-123355","article-title":"Double-blind, randomized study of canakinumab treatment in pediatric and young adult patients with sickle cell anemia.","volume":"134","author":"Rees","year":"2019","journal-title":"Blood"},{"key":"B94","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1056\/NEJMoa1609677","article-title":"Gene therapy in a patient with sickle cell disease.","volume":"376","author":"Ribeil","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B95","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.2999980","article-title":"Enzymatic amplification of b-globin genomic sequences and restriction site analysis for diagnosis of sickle cell anaemia.","volume":"230","author":"Saiki","year":"1985","journal-title":"Science"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1759","DOI":"10.1016\/j.bbmt.2018.03.031","article-title":"Haploidentical peripheral blood stem cell transplantation demonstrates stable engraftment in adults with sickle cell disease.","volume":"24","author":"Saraf","year":"2018","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0192710","article-title":"Causes of death and early life determinants of survival in homozygous sickle cell disease: the Jamaican cohort study from birth.","volume":"13","author":"Serjeant","year":"2018","journal-title":"PLoS One"},{"key":"B98","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2040620713483063","article-title":"Hematopoietic stem-cell transplantation for sickle cell disease: current evidence and opinions.","volume":"4","author":"Shenoy","year":"2013","journal-title":"Ther. Adv. Hematol."},{"key":"B99","doi-asserted-by":"publisher","first-page":"1598","DOI":"10.1182\/bloodadvances.2017007211","article-title":"Pharmacotherapeutical strategies in the prevention of acute, vaso-occlusive pain in sickle cell disease: a systematic review.","volume":"1","author":"Sins","year":"2017","journal-title":"Blood Adv."},{"key":"B100","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1182\/blood-2013-08-523936","article-title":"Differential contribution of FXa and thrombin to vascular inflammation in a mouse model of sickle cell disease.","volume":"123","author":"Sparkenbaugh","year":"2014","journal-title":"Blood"},{"key":"B101","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/bjh.12336","article-title":"Interplay between coagulation and vascular inflammation in sickle cell disease.","volume":"162","author":"Sparkenbaugh","year":"2013","journal-title":"Br. J. Haematol."},{"key":"B102","author":"Steinberg","year":"2001","journal-title":"Disorders of Hemoglobin: Genetics, Pathophysiology, and Clinical Management"},{"key":"B103","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1021\/acs.bioconjchem.9b00130","article-title":"Interactions of an anti-sickling drug with hemoglobin in red blood cells from a patient with sickle cell anemia.","volume":"30","author":"Strader","year":"2019","journal-title":"Bioconjug. Chem."},{"key":"B104","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1146\/annurev-pathmechdis-012418-012838","article-title":"Pathophysiology of sickle cell disease.","volume":"14","author":"Sundd","year":"2019","journal-title":"Annu. Rev. Pathol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1182\/blood-2015-09-618553","article-title":"Beyond hydroxyurea: new and old drugs in the pipeline for sickle cell disease.","volume":"127","author":"Telen","year":"2016","journal-title":"Blood"},{"key":"B106","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1111\/bjh.14303","article-title":"Sevuparin binds to multiple adhesive ligands and reduces sickle red blood cell-induced vaso-occlusion.","volume":"175","author":"Telen","year":"2016","journal-title":"Br. J. Haematol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41573-018-0003-2","article-title":"Therapeutic strategies for sickle cell disease: towards a multi-agent approach.","volume":"18","author":"Telen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"B108","doi-asserted-by":"publisher","first-page":"2656","DOI":"10.1182\/blood-2014-06-583351","article-title":"Randomized phase 2 study of GMI-1070 in SCD: reduction in time to resolution of vaso-occlusive events and decreased opioid use.","volume":"125","author":"Telen","year":"2015","journal-title":"Blood"},{"key":"B109","doi-asserted-by":"publisher","first-page":"905","DOI":"10.3324\/haematol.10937","article-title":"Clinical outcomes in children with sickle cell disease living in England: a neonatal cohort in East London.","volume":"92","author":"Telfer","year":"2007","journal-title":"Haematologica"},{"key":"B110","doi-asserted-by":"publisher","first-page":"539","DOI":"10.3324\/haematol.2019.224709","article-title":"Hemolytic transfusion reactions in sickle cell disease: underappreciated and potentially fatal.","volume":"105","author":"Thein","year":"2020","journal-title":"Haematologica"},{"key":"B111","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1056\/NEJMe1906771","article-title":"Targeted agent for sickle cell disease - changing the protein but not the gene.","volume":"381","author":"Thompson","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1038\/nm.4170","article-title":"A genome-editing strategy to treat beta-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.","volume":"22","author":"Traxler","year":"2016","journal-title":"Nat. Med."},{"key":"B113","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1056\/NEJMoa1813598","article-title":"Hydroxyurea for children with sickle cell anemia in sub-saharan Africa.","volume":"380","author":"Tshilolo","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010155.pub3","article-title":"Low-molecular-weight heparins for managing vaso-occlusive crises in people with sickle cell disease.","volume":"6","author":"van Zuuren","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"B115","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1056\/NEJMoa1903212","article-title":"A phase 3 randomized trial of voxelotor in sickle cell disease.","volume":"381","author":"Vichinsky","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"B116","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1056\/NEJM199006073222301","article-title":"Alloimmunization in sickle cell anemia and transfusion of racially unmatched blood.","volume":"322","author":"Vichinsky","year":"1990","journal-title":"N. Engl. J. Med."},{"key":"B117","doi-asserted-by":"publisher","first-page":"2166","DOI":"10.1182\/blood-2006-12-061697","article-title":"Platelet activation in patients with sickle disease, hemolysis-associated pulmonary hypertension, and nitric oxide scavenging by cell-free hemoglobin.","volume":"110","author":"Villagra","year":"2007","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1111\/bjh.15038","article-title":"Recent progress in understanding and manipulating haemoglobin switching for the haemoglobinopathies.","volume":"180","author":"Vinjamur","year":"2018","journal-title":"Br. J. Haematol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1056\/NEJMp1700101","article-title":"Sickle cell disease - a history of progress and peril.","volume":"376","author":"Wailoo","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B120","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.bbmt.2009.10.005","article-title":"Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease.","volume":"16","author":"Walters","year":"2010","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B121","first-page":"100","article-title":"Barriers to bone marrow transplantation for sickle cell anemia.","volume":"2","author":"Walters","year":"","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B122","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1002\/ajh.24995","article-title":"Bone marrow transplantation for sickle cell disease.","volume":"335","author":"Walters","year":"","journal-title":"N. Engl. J. Med."},{"key":"B123","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1053\/bbmt.2001.v7.pm11787529","article-title":"Stable mixed hematopoietic chimerism after bone marrow transplantation for sickle cell anemia.","volume":"7","author":"Walters","year":"2001","journal-title":"Biol. Blood Marrow Transplant."},{"key":"B124","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1016\/S0140-6736(11)60355-3","article-title":"Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG).","volume":"377","author":"Wang","year":"2011","journal-title":"Lancet"},{"key":"B125","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1182\/asheducation-2015.1.436","article-title":"Optimizing hydroxyurea therapy for sickle cell anemia.","volume":"2015","author":"Ware","year":"2015","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B126","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1182\/asheducation-2009.1.62","article-title":"Advances in the use of hydroxyurea.","volume":"2009","author":"Ware","year":"2009","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"B127","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/S0140-6736(15)01041-7","article-title":"Hydroxycarbamide versus chronic transfusion for maintenance of transcranial doppler flow velocities in children with sickle cell anaemia-TCD with transfusions changing to hydroxyurea (TWiTCH): a multicentre, open-label, phase 3, non-inferiority trial.","volume":"387","author":"Ware","year":"2016","journal-title":"Lancet"},{"key":"B128","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1002\/pbc.23145","article-title":"Stroke with transfusions changing to hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload.","volume":"57","author":"Ware","year":"2011","journal-title":"Pediatr. Blood Cancer"},{"key":"B129","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1016\/j.tig.2018.09.004","article-title":"Wake-up sleepy gene: reactivating fetal globin for beta-hemoglobinopathies.","volume":"34","author":"Wienert","year":"2018","journal-title":"Trends Genet."},{"key":"B130","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1146\/annurev-genom-083117-021320","article-title":"Sickle cell anemia and its phenotypes.","volume":"19","author":"Williams","year":"2018","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"B131","doi-asserted-by":"publisher","first-page":"3628","DOI":"10.1073\/pnas.79.11.3628","article-title":"Use of restriction endonucleases for mapping the allele for beta s-globin.","volume":"79","author":"Wilson","year":"1982","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B132","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/s0022-2143(97)90005-6","article-title":"Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell anemia.","volume":"129","author":"Wun","year":"1997","journal-title":"J. Lab. Clin. Med."},{"key":"B133","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1182\/blood-2015-09-618538","article-title":"Neutrophils, platelets, and inflammatory pathways at the nexus of sickle cell disease pathophysiology.","volume":"127","author":"Zhang","year":"2016","journal-title":"Blood"}],"container-title":["Frontiers in Physiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2020.00435\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T23:37:59Z","timestamp":1615851479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphys.2020.00435\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":133,"alternative-id":["10.3389\/fphys.2020.00435"],"URL":"https:\/\/doi.org\/10.3389\/fphys.2020.00435","relation":{},"ISSN":["1664-042X"],"issn-type":[{"value":"1664-042X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]},"article-number":"435"}}